Abonnement à la biblothèque: Guest

Current Trends in Therapeutics for Colon Cancer

Volume 8, Numéro 2, 2021, pp. 93-104
DOI: 10.1615/ForumImmunDisTher.2021038950
Get accessDownload

RÉSUMÉ

Colon cancer (CC) is the third most common cancer diagnosed worldwide, making it a serious global challenge. Metastasis is mainly responsible for high mortality in CC patients. In CC patients, a mutation in Kirsten rat sarcoma (KRAS), adenomatous polyposis coli (APC), and tumor protein 53 (TP53) mainly drives the metastasis, mediates drug resistance, and promotes tumor recurrence by maintaining stem cell phenotype. Recently, long noncoding RNAs (lncRNAs) were reported to mediate KRAS-, APC-, and TP53-dependent CC progression and metastasis. In the present review, we have discussed the current updates on lncRNAs dependent on KRAS, APC, and TP53 in CC progression and metastasis. We also presented current trends in targeted therapies, immune therapies, redox-based therapies, and phytochemical-based therapies for CC. Finally, nanosystems for targeted delivery of therapeutic agents, which limit drug resistance and drug toxicities, were discussed. Therefore, targeted therapeutics can be used for CC treatment at the clinical stage.

RÉFÉRENCES
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

  2. Wilkins T, McMechan D, Talukder A, Herline A. Colorectal cancer screening and surveillance in individuals at increased risk. Am Fam Physician. 2018;97(2):111-6.

  3. Wilkins T, McMechan D, Talukder A. Colorectal cancer screening and prevention. Am Fam Physician. 2018;97(10):658-65.

  4. Rasmy A, Fayed A, Omar A, Fahmy N. Effect of KRAS mutational status on disease behavior and treatment out-come in patients with metastatic colorectal cancer: Intra-tumor heterogeneity and mutational status. J Gastrointest Oncol. 2019;10(5):886-95.

  5. Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, Liu L, Huang G, Liu J, Zhao X. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38(1):401.

  6. Carrer A, Trefely S, Zhao S, Campbell SL, Norgard RJ, Schultz KC, Sidoli S, Parris JLD, Affronti HC, Sivanand S, Egolf S, Sela Y, Trizzino M, Gardini A, Garcia BA, Snyder NW, Stanger BZ, Wellen KE. Acetyl-CoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019;9(3):416-35.

  7. Gallegos-Arreola MP, Zuniga-Gonzalez GM, Gomez-Mariscal K, Rosales-Reynoso MA, Luis L, Puebla-Perez AM, Pineda-Razo T. Association of rs712 polymorphism in a let-7 microRNA-binding site of KRAS gene with colorectal cancer in a Mexican population. Iran J Basic Med Sci. 2019;22(3):324-7.

  8. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15(6):489-500.

  9. Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer. 2018;143(4):921-30.

  10. Papoutsoglou P, Moustakas A. Long non-coding RNAs and TGF-P signaling in cancer. Cancer Sci. 2020;111(8): 2672-81.

  11. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329-59.

  12. Andre T, de Gramont A, Vernerey D. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MO-SAIC study. J Clin Oncol. 2015;33:4176-87.

  13. Zhai H, Zhang X, Sun X, Zhang D, Ma S. Long non-coding RNA LINC01420 contributes to pancreatic cancer progression through targeting KRAS proto-oncogene. Dig Dis Sci. 2020;65(4):1042-52.

  14. Yue B, Liu C, Sun H, Liu M, Song C, Cui R, Qiu S, Zhong M. A positive feed-forward loop between lncRNA-CY-TOR and Wnt/p-catenin signaling promotes metastasis of colon cancer. Mol Ther. 2018;26(5):1287-98.

  15. Wang L, Wei Z, Wu K, Dai W, Zhang C, Peng J, He Y. Long noncoding RNA B3GALT5-AS1 suppresses colon cancer liver metastasis via repressing microRNA-203. Aging. 2018;10(12):3662-82.

  16. Cheng B, Rong A, Zhou Q, Li W. lncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway. J Exp Clin Cancer Res. 2020;39(1):5.

  17. Sun Y, Li M, Liu G, Zhang X, Zhi L, Zhao J, Wang G. The function of Piezo1 in colon cancer metastasis and its potential regulatory mechanism. J Cancer Res Clin Oncol. 2020;146(5):1139-52.

  18. Wang M, Su Z, Amoah Barnie P. Crosstalk among colon cancer-derived exosomes, fibroblast-derived exosomes, and macrophage phenotypes in colon cancer metastasis. Int Immunopharmacol. 2020;81:106298.

  19. Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T, Wu L, Zhang T, Sun X, Zhong L, Zhou C, Wang Z, Peng Z, Chen J, Wang X. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res. 2016;35(1):148.

  20. Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, Ochiai A, Nakayama KI, Mimori K, Suzuki Y, Hong CP, Ock CY, Kim SJ, Oshima M. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 2018;78(5):1334-46.

  21. Yang Y, Junjie P, Sanjun C, Ma Y. Long non-coding RNAs in colorectal cancer: Progression and future directions. J Cancer. 2017;8(16):3212-25.

  22. Wang FW, Cao CH, Han K, Zhao YX, Cai MY, Xiang ZC, Zhang JX, Chen JW, Zhong LP, Huang Y, Zhou SF, Jin XH, Guan XY, Xu RH, Xie D. APC-activated long non-coding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. J Clin Invest. 2019;129(2):727-43.

  23. Li Y, Lauriola M, Kim D, Francesconi M, D'Uva G, Shibata D, Malafa MP, Yeatman TJ, Coppola D, Solmi R, Cheng JQ. Adenomatous polyposis coli (APC) regulates miR17-92 cluster through P-catenin pathway in colorectal cancer. Oncogene. 2016;35(35):4558-68.

  24. Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019;11(4):267-76.

  25. Di Agostino S. The impact of mutant p53 in the non-coding RNA world. Biomolecules. 2020;10(3):472.

  26. Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D, Lu Z, Bai C, Watabe K, Mo Y-Y. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23(3):340-50.

  27. Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin 3rd EF, Cassidy DP, Marx, Rybkin, II MA, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54-71.

  28. Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Muller H, Baumann M, Schultz-Fademrecht C, Gunther G, Maghnouj A, Muller MP, Pohl M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D. Preclinical efficacy of covalent-allosteric AKT inhibitor borussertib in combination with trametinib in KRAS-mutant pancreatic and colorectal cancer. Cancer Res. 2019;79(9):2367-78.

  29. Wang G, Huang Y, Wu Z, Zhao C, Cong H, Ju S, Wang X. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib. Biosci Rep. 2019;39(3):BSR20181786.

  30. Lin MH, Wang JS, Hsieh YC, Zheng JH, Cho EC. NO(2) functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer. Chem Biol Interact. 2019;309:108708.

  31. Huang TH, Wu SY, Huang YJ, Wei PL, Wu AT, Chao TY. The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells. Am J Cancer Res. 2017;7(5):1227-37.

  32. Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019;30(11):1796-1803.

  33. Pek M, Yatim S, Chen Y, Li J, Gong M, Jiang X, Zhang F, Zheng J, Wu X, Yu Q. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene. 2017;36(35):4975-86.

  34. Kim S, Kim N, Kang K, Kim W, Won J, Cho J. Whole transcriptome analysis identifies TNS4 as a key effector of cetuximab and a regulator of the oncogenic activity of KRAS mutant colorectal cancer cell lines. Cells. 2019;8(8):878.

  35. Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, Lo-Conte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in re-fractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs. 2016;34(2):168-75.

  36. Almeida LC, Bauermeister A, Rezende-Teixeira P, Santos EAD, Moraes LAB, Machado-Neto JA, Costa-Lotufo LV. Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells. Biochem Pharmacol. 2019;168:38-47.

  37. Inoue A, Mizushima T, Wu X, Okuzaki D, Kambara N, Ishikawa S, Wang J, Qian Y, Hirose H, Yokoyama Y, Ikeshima R, Hiraki M, Miyoshi N, Takahashi H, Haraguchi N, Hata T, Matsuda C, Doki Y, Mori M, Yamamoto H. A miR-29b by product sequence exhibits potent tumor-suppressive activities via inhibition of NF-KB signaling in KRAS-mutant colon cancer cells. Mol Cancer Ther. 2018;17(5):977-87.

  38. Wang W, Zhang L, Morlock L, Williams NS, Shay JW, De Brabander JK. Design and synthesis of TASIN analogues specifically targeting colorectal cancer cell lines with mutant adenomatous polyposis coli (APC). J Med Chem. 2019;62(10):5217-41.

  39. Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem. 2018;293(38):14891-904.

  40. Gupta R, Bhatt LK, Johnston TP, Prabhavalkar KS. Colon cancer stem cells: Potential target for the treatment of colorectal cancer. Cancer Biol Ther. 2019;20(8):1068-82.

  41. Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Yousefi B, Jadidi-Niaragh F. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins Other Lipid Mediat. 2019;144:106338.

  42. Wang J, Cai H, Liu Q, Xia Y, Xing L, Zuo Q, Zhang Y, Chen C, Xu K, Yin P, Chen T. Cinobufacini inhibits colon cancer invasion and metastasis via suppressing Wnt/p-catenin signaling pathway and EMT. Am J Chin Med. 2020;48(3):703-18.

  43. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A, Gao R, Orf J, Wang T, Sawant D, Kang J, Bhatt D, Lu D, Li C-M, Rapaport AS, Perez K, Ye Y, Wang S, Hu X, Ren X, Ouyang W, Shen Z, Egen JG, Zhang Z, Yu X. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181(2):442-59.e29.

  44. Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Sanchez Rodriguez I, Cancelliere C, Banerjee R, Schipper LJ, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, Yang F, Uk Group CMN, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest EE, Bardelli A, Garnett MJ. Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy and immunotherapy. Cancer Discov. In press 2021.

  45. Johdi NA, Sukor NF. Colorectal cancer immunotherapy: Options and strategies. Front Immunol. 2020;11:1624.

  46. Wang X, Luo X, Tian Y, Wu T, Weng J, Li Z, Ye F, Huang X. Equipping natural killer cells with cetuximab through metabolic glycoengineering and bioorthogonal reaction for targeted treatment of KRAS mutant colorectal cancer. ACS Chem Biol. 2021;16(4):724-30.

  47. Bahmani B, Gong H, Luk BT, Haushalter KJ, DeTeresa E, Previti M, Zhou J, Gao W, Bui JD, Zhang L, Fang RH, Zhang J. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat Commun. 2021;12(1):1999.

  48. Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, Zheng S, Kerr D, Samsonova A, La Thangue NB. Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol. In press 2021.

  49. Bao XZ, Dai F, Wang Q, Jin XL, Zhou B. Developing glutathione-activated catechol-type diphenylpolyenes as small molecule-based and mitochondria-targeted prooxidative anticancer theranostic prodrugs. Free Radic Biol Med. 2019;134:406-18.

  50. Liu S, Zhou Y, Hu C, Cai L, Pang M. Covalent organic framework-based nanocomposite for synergetic photo-, chemodynamic, and immunotherapies. ACS Appl Mater Interfaces. 2020;12(39):43456-65.

  51. Schroeter A, Aichinger G, Stornig K, Marko D. Impact of oxidative metabolism on the cytotoxic and genotoxic potential of genistein in human colon cancer cells. Mol Nutr Food Res. 2019;63(2):e1800635.

  52. Vidimar V, Licona C, Ceron-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C. A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. Cancer Lett. 2019;440-1:145-55.

  53. Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo HY, Chen Y, Tian T, Wang Y, Kang TB, Xie D, Zeng MS, Huang P, Xu RH. Disrupting G6PD-mediated redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 2017;36(45):6282-92.

  54. Dariya B, Muppala S, Srivani G, Momin S, Alam A, Saddala MS. Targeting STAT proteins via computational analysis in colorectal cancer. Mol Cell Biochem. 2021;476(1):165-74.

  55. Ganesan K, Jayachandran M, Xu B. Diet-derived phyto-chemicals targeting colon cancer stem cells and microbiota in colorectal cancer. Int J Mol Sci. 2020;21(11):3976.

  56. Yapasert R, Sripanidkulchai B, Teerachaisakul M, Banchuen K, Banjerdpongchai R. Anticancer effects of a traditional Thai herbal recipe Benja Amarit extracts against human hepatocellular carcinoma and colon cancer cell by targeting apoptosis pathways. J Ethnopharmacol. 2020;254:112732.

  57. Ruvinov I, Nguyen C, Scaria B, Vegh C, Zaitoon O, Baskaran K, Mehaidli A, Nunes M, Pandey S. Lemongrass extract possesses potent anticancer activity against human colon cancers, inhibits tumorigenesis, enhances efficacy of FOLFOX, and reduces its adverse effects. Integr Cancer Ther. 2019;18:1534735419889150.

  58. Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, Sun B, Chen B, Xiao Z. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnol. 2020;18(1):10.

  59. Al-Ani LA, Yehye WA, Kadir FA, Hashim NM, AlSaadi MA, Julkapli NM, Hsiao VKS. Hybrid nanocomposite curcumin-capped gold nanoparticle-reduced graphene oxide: Anti-oxidant potency and selective cancer cytotoxicity. PLoS One. 2019;14(5):e0216725.

  60. Babaei M, Abnous K, Taghdisi SM, Taghavi S, Sh Saljooghi A, Ramezani M, Alibolandi M. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA into colon adenocarcinoma in vitro and in vivo. Eur J Pharm Bio-pharm. 2020;156:84-96.

  61. Alkhatib MH, Aljadani MA, Mahassni SH. Carrying epirubicin on nanoemulsion containing algae and cinnamon oils augments its apoptotic and anti-invasion effects on human colon cancer cells. Am J Transl Res. 2020;12(6):2463-72.

  62. Bauleth-Ramos T, Feijao T, Gonjalves A, Shahbazi MA, Liu Z, Barrias C, Oliveira MJ, Granja P, Santos HA, Sarmento B. Colorectal cancer triple co-culture spheroid model to assess the biocompatibility and anticancer properties of polymeric nanoparticles. J Control Release. 2020;323:398-411.

  63. Gou S, Huang Y, Sung J, Xiao B, Merlin D. Silk fibroin-based nanotherapeutics: Application in the treatment of colonic diseases. Nanomedicine. 2019;14(17):2373-8.

  64. Habib S, Daniels A, Ariatti M, Singh M. Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro. F1000Res. 2020;9:770.

  65. Li C, Cai G, Song D, Gao R, Teng P, Zhou L, Ji Q, Sui H, Cai J, Li Q, Wang Y. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer. Biomater Sci. 2019;7(9):3627-39.

  66. Sridharan K, Rathore B, Yousuf M, Reddy Rachamalla HK, Jinka S, Jaggarapu M, Banerjee R. Self-assembling derivative of hydrocortisone as glucocorticoid receptor-targeted nanotherapeutics for synergistic, combination therapy against colorectal tumor. Mol Pharm. 2021;18(3):1208-28.

  67. Pinho JO, da Silva IV, Amaral JD, Rodrigues CMP, Casini A, Soveral G, Gaspar MM. Therapeutic potential of a copper complex loaded in pH-sensitive long circulating liposomes for colon cancer management. Int J Pharm. 2021;599:120463.

  68. Jiang Y, Guo Z, Fang J, Wang B, Lin Z, Chen ZS, Chen Y, Zhang N, Yang X, Gao W. A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. Mater Sci Eng C Mater Biol Appl. 2020;107:110224.

  69. Chen C, Zhou L, Xie B, Wang Y, Ren L, Chen X, Cen B, Lv H, Wang H. Novel fast-acting pyrazole/pyridine-functionalized N-heterocyclic carbene silver complexes assembled with nanoparticles show enhanced safety and efficacy as anticancer therapeutics. Dalton Trans. 2020;49(8):2505-16.

  70. Mei T, Shashni B, Maeda H, Nagasaki Y. Fibrinolytic tissue plasminogen activator installed redox-active nanoparticles (t-PAiRNP) for cancer therapy. Biomaterials. 2020;259:120290.

  71. Xie K, Song S, Zhou L, Wan J, Qiao Y, Wang M, Xie H, Zhou L, Zheng S, Wang H. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly. Int J Pharm. 2019;556:159-71.

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain